Who are Aldara Cream 5%'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): standard dose of HCQ, Imiquimod 5% Topical Cream, Imiquimod and Interferon alpha, Aldara (imiquimod) cream, 5%, PIFB with adjuvants, Imiquimod 3.75% Cream.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aldara-cream-5.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Aldara Cream 5% — Competitive Intelligence Brief

Aldara Cream 5% (Aldara Cream 5%) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Toll-like receptor 7 (TLR7) agonist. Area: Dermatology/Oncology.

marketed Toll-like receptor 7 (TLR7) agonist TLR7 Dermatology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Aldara Cream 5% (Aldara Cream 5%) — Hordinsky, Maria K., MD. Imiquimod is a toll-like receptor 7 (TLR7) agonist that activates innate immune responses to treat skin lesions.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Aldara Cream 5% TARGET	Aldara Cream 5%	Hordinsky, Maria K., MD	marketed	Toll-like receptor 7 (TLR7) agonist	TLR7
standard dose of HCQ	standard dose of HCQ	University of Sao Paulo General Hospital	marketed	Antimalarial immunosuppressant	Toll-like receptors (TLR7, TLR9); phospholipase C
Imiquimod 5% Topical Cream	Imiquimod 5% Topical Cream	University of Michigan	marketed	Toll-like receptor 7 (TLR7) agonist	TLR7
Imiquimod and Interferon alpha	Imiquimod and Interferon alpha	The University of Texas Health Science Center, Houston	marketed	Immunostimulant combination	TLR7/8 (imiquimod); Interferon-alpha receptor (interferon alpha)
Aldara (imiquimod) cream, 5%	Aldara (imiquimod) cream, 5%	Graceway Pharmaceuticals, LLC	marketed	TLR7 agonist	TLR7 (Toll-like receptor 7)
PIFB with adjuvants	PIFB with adjuvants	Wake Forest University Health Sciences	marketed	Immunostimulatory vaccine	TLR3, TLR7/8
Imiquimod 3.75% Cream	Imiquimod 3.75% Cream	Medical University of Graz	marketed	TLR7 agonist	TLR7 (Toll-like receptor 7)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Toll-like receptor 7 (TLR7) agonist class)

Hordinsky, Maria K., MD · 1 drug in this class
University Medical Centre Maribor · 1 drug in this class
University of Michigan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Aldara Cream 5% — Competitive Intelligence Brief. https://druglandscape.com/ci/aldara-cream-5. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab